Anesthetic Agents Library
ISO 17025–ACCREDITED LABORATORY ENVIRONMENT
Anesthetic Agents DMPK and Bioanalytical Services
Anesthetic agent bioanalysis is defined by one compound that reverses the metabolic order. Lidocaine, bupivacaine, and ketamine follow the expected CYP Phase I metabolism with NADPH cofactor. Propofol does not: its primary clearance route is UGT1A9 Phase II glucuronidation (UDPGA), with CYP2B6 Phase I as a secondary pathway. Every other dual-cofactor compound in this library — buprenorphine, olanzapine, valproic acid — lists Phase I first and Phase II second. Propofol lists Phase II first because glucuronidation is the primary route. A NADPH-only incubation that correctly serves lidocaine, bupivacaine, and ketamine will capture propofol’s secondary CYP2B6 route but miss UGT1A9 glucuronidation — the primary clearance pathway.
Creative Proteomics provides CYP Phase I metabolism for lidocaine, bupivacaine, and ketamine; dual-cofactor Phase II+Phase I profiling for propofol; and custom multi-anesthetic panels with cofactor-matched incubation arms.
Three CYP Phase I (NADPH-Only)Lidocaine, bupivacaine, and ketamine follow CYP-mediated Phase I metabolism with standard NADPH cofactor.
Propofol: Phase II First, Phase I SecondUGT1A9 glucuronidation (UDPGA) is the primary route; CYP2B6 is secondary. CoFactor order is reversed from every other dual-compound in this library.
Dual-Cofactor for Propofol OnlyNADPH+UDPGA dual-cofactor incubation required. Standard NADPH-only protocols miss the primary clearance route.
Anesthetic Cofactor Divide DMPK Strategy Map
⚡
Cofactor ClassificationLidocaine, bupivacaine, ketamine: NADPH-only CYP Phase I. Propofol: NADPH+UDPGA dual-cofactor with Phase II as the primary route — reversed order from every other dual-cofactor compound in this library.
🧬
CYP Phase I Metabolism (NADPH)Lidocaine (CYP1A2/3A4), bupivacaine (CYP3A4/1A2), ketamine (CYP3A4/2B6/2C9) — standard NADPH-supplemented incubation.
📊
Phase II + Phase I Dual-Cofactor (Propofol)UGT1A9 glucuronidation (UDPGA) primary + CYP2B6 oxidation (NADPH) secondary. Both cofactors in one incubation.
🔬
Structural Redundancy: Lidocaine = BupivacaineLidocaine and bupivacaine share CYP1A2 and CYP3A4 — identical enzyme profile, identical cofactor, identical incubation conditions. A shared method serves both.
Anesthetic cofactor audit before method development.Creative Proteomics classifies each agent as NADPH-only (CYP Phase I) or NADPH+UDPGA (Phase II primary + Phase I secondary) — because propofol’s Phase II-first metabolic order means a standard NADPH protocol captures the secondary CYP2B6 route but misses the primary UGT1A9 clearance pathway.
